They were able to identify further DLBCL subsets: low-risk ABC DLBCLs of extrafollicular/marginal zone origin; two distinct subsets of GCB DLBCLs with different outcomes and targetable alterations; and an ABC/GCB-independent group with biallelic inactivation of TP53, CDKN2A loss and associated genomic instability. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.